CAM
IOVA icon

Cormorant Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Cormorant Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-505,941
Closed -$4.16M – 84
2016
Q3 		$4.16M Hold
505,941
– – 0.46% 56
2016
Q2 		$4.1M Buy
505,941
+6,126
+1% +$38.5K 0.58% 48
2016
Q1 		$2.54M Hold
499,815
– – 0.38% 58
2015
Q4 		$3.86M Hold
499,815
– – 0.46% 51
2015
Q3 		$2.88M Hold
499,815
– – 0.46% 50
2015
Q2 		$4.58M Buy
499,815
+75,000
+18% +$837K 0.61% 43
2015
Q1 		$5.14M Buy
+424,815
New +$4.78M 0.8% 40

Other funds holding IOVA

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cormorant Asset Management's IOVA Position: Q4 2016 in Review

Cormorant Asset Management sold out of Iovance Biotherapeutics (IOVA) in Q4 2016, closing a stake of 505,941 shares — an estimated $4.16M sold.

Cormorant Asset Management first reported a position in IOVA in Q1 2015 and held it in 7 quarters. The position peaked at $5.14M in Q1 2015. 87 funds tracked by Wall St. Rank hold IOVA as of Q4 2016.

  • Cormorant Asset Management reported no remaining Iovance Biotherapeutics position as of Q4 2016 after selling out during the quarter.
  • Cormorant Asset Management sold 505,941 Iovance Biotherapeutics shares in Q4 2016, an estimated $4.16M.
  • Cormorant Asset Management first reported a position in Iovance Biotherapeutics in Q1 2015 and held it in 7 quarters.
  • Cormorant Asset Management's Iovance Biotherapeutics position peaked at $5.14M in Q1 2015.
  • 87 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2016.

Based on Cormorant Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.